Table 1.
Characteristics of patients according to seroreversion of anti-spike and anti-nucleocapsid IgG antibodies.
| Anti-spike IgG antibodies | Anti-nucleocapsid IgG antibodies | |||||||
|---|---|---|---|---|---|---|---|---|
| 12 month non-seroreversion N = 73 | 12-month seroreversion N = 7 | P | Adjusted OR (95% CI) | 12 month non-seroreversion N = 35 | 12-month seroreversion N = 45 | P | Adjusted OR (95% CI) | |
| Sex, men | 44 (60.3) | 5 (71.4) | 0.700 | 19 (54.3) | 30 (66.7) | 0.355 | ||
| Age | 60 (53–69) | 52 (38–66.5) | 0.247 | 60 (58–71.5) | 57 (46–67) | 0.047 | 0.96 (0.91–1.02) | |
| Comorbidity | 43 (58.9) | 6 (85.7) | 0.239 | 22 (62.9) | 27 (60.0) | 0.821 | ||
| Highest WHO severity score (range) | 4 (4–6) | 4 (3–6) | 0.261 | 4 (4–6) | 4 (3–6) | 0.584 | ||
| ICU admission | 13 (17.8) | 0 | 0.592 | 6 (17.1) | 7 (15.6) | 1.0 | ||
| Hospital stay, days | 12 (9–17) | 6 (4–9.5) | 0.055 | 1.08 (0.86–1.44) | 13 (9.5–16) | 10.5 (6–13) | 0.015 | 0.96 (0.85–1.09) |
| Peak SARS-CoV-2 RNA, copies/sample | 5957 (1265–37,229) | 13,015 (2580–27,723) | 0.861 | 12,857 (5445–41,256) | 2989 (830–27,723) | 0.024 | ||
| Initial Ct, N-gen | 32.6 (29.5–35.4) | 32.6 (29.8–35.7) | 0.965 | 30.5 (28.8–34.1) | 33.8 (30.8–36.4) | 0.019 | 1.14 (1.00–1.33) | |
| Initial Ct, E-gen | 30.1 (26.9–33.4) | 30.4 (27.2–38.0) | 0.982 | 28.8 (26–30.7) | 32 (28.2–40) | 0.016 | ||
| Days to viral clearance | 20 (6–48) | 35 (4–46) | 0.862 | 20 (11–56) | 20.5 (4–37.8) | 0.303 | ||
| Days to seroconversion S-IgG | 15 (12–20) | 19 (12–67) | 0.335 | 16 (12–22) | 15 (12–19) | 0.652 | ||
| Days to seroconversion N-IgG | 12 (9–17) | 17 (5.5–36) | 0.623 | 11.5 (9–14.8) | 13 (10–18) | 0.238 | ||
| Peak S-IgG, S/CO | 6.9 (6.2–12.4) | 1.7 (1.6–3.3) | <0.001 | 0.19 (0.04–0.45) | 7.1 (5.9–13.5) | 6.6 (5.9–7.6) | 0.150 | |
| Peak N-IgG, S/CO | 4.7 (4.1–6.7) | 2.3 (1.6–3.8) | 0.008 | 0.72 (0.30–1.31) | 5.4 (4.4–9.4) | 4.3 (3.5–4.9) | <0.001 | 0.71 (0.53–0.90) |
| COVID-19 immune therapy | ||||||||
| Steroids | 15 (20.5) | 1 (14.3) | 1.0 | 8 (22.9) | 8 (17.8) | 0.587 | ||
| Tocilizumab | 49 (67.1) | 3 (42.9) | 0.232 | 23 (65.7) | 29 (64.4) | 1.0 | ||
Continuous variables are expressed as median (interquartile range) and categorical as number (%), unless indicated.
OR, odds ratio; CI, confidence interval; ICU, intensive care unit; Ct, cycle threshold of SARS-CoV-2 RT-PCR; S-IgG, anti-spike-IgG; N-IgG, anti-nucleocapsid-IgG; S/CO, absorbance/cutoff.